Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizer's report of Annual General Meeting held on July 10, 2026, and informed the Exchange regarding voting results. The company has received approval for financial statements, dividend declaration, and director re-appointment, with all resolutions passed with significant majorities.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited held its 22nd Annual General Meeting on July 10, 2026, through video conferencing. The meeting was attended by the Managing Director, Chief Financial Officer, Company Secretary, and representatives of the Statutory Auditors and Secretarial Auditors. The Chairman presented the Financial Highlights for FY 2025-26, including a proposed dividend, and discussed the Company's growth strategy, innovation, and commitment to sustainability and governance.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has received a certificate from MUFG Intime India Private Limited, its Registrar & Share Transfer Agent, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited's wholly-owned subsidiary, Maxcure Nutravedics Limited, has had a penalty of INR 3,59,10,000/- imposed by the Deputy Commissioner of State Tax, Gujarat, set-aside by the First Appellate Authority, Ahmedabad, Gujarat.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has closed its trading window for designated persons from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ending June 30, 2026.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has announced the publication of newspaper advertisements for its 22nd Annual General Meeting (AGM). These advertisements appeared in Business Standard (English and Hindi) on June 19, 2026. The AGM is scheduled to be held on Friday, July 10, 2026, at 11:00 AM (IST) via Video Conferencing or other audio means. This procedural announcement, made in compliance with SEBI regulations, provides shareholders with crucial information for attending and participating in the company's annual governance process.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has announced it has sent letters to shareholders who have not registered their email IDs. These letters provide a web-link to the company's Integrated Annual Report for the Financial Year 2025-26. This action is taken pursuant to Regulation 36(1)(b) of SEBI Listing Regulations, ensuring compliance with disclosure requirements. For investors, this update highlights the company's commitment to transparent communication and facilitating access to important financial information for all shareholders. No new financial figures or strategic decisions were announced in this procedural update.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report for the Financial Year 2025-26, as per Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 10, 2026. The meeting will consider and adopt the audited standalone and consolidated financial statements for the financial year ended on March 31, 2026, and the reports of the Board of Directors and Auditors. The meeting will also consider the re-appointment of Mr. Sanjay Sinha as Director, ratify the remuneration of Cost Auditors, and approve the revision in remuneration of Mr. Sanjeev Jain, Managing Director and Promoter.